EGFR and colorectal carcinoma: In the case of cetuximab and panitumumab, antibodies targeting the epidermal growth factor receptor (EGFR), prospective and retrospective analyses in patients with colorectal cancer (CRC) established the importance of KRAS mutations on sensitivity to these agents [8–10].